89bio, Inc. – NASDAQ:ETNB
89bio stock price today
$9
+1.12
+14.21%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
89bio stock price monthly change
-10.25%
month
89bio stock price quarterly change
-10.25%
quarter
89bio stock price yearly change
-29.07%
year
89bio key metrics
Market Cap | 918.31M |
Enterprise value | 463.56M |
P/E | -4.79 |
EV/Sales | N/A |
EV/EBITDA | -4.54 |
Price/Sales | N/A |
Price/Book | 3.28 |
PEG ratio | -0.13 |
EPS | -2.01 |
Revenue | N/A |
EBITDA | -175.29M |
Income | -165.03M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for free89bio stock price history
89bio stock forecast
89bio financial statements
| Jun 2023 | 0 | -38.39M | |
|---|---|---|---|
| Sep 2023 | 0 | -34.72M | |
| Dec 2023 | 234K | -40.23M | -17194.44% |
| Mar 2024 | 0 | -51.68M |
| Dec 2023 | 234K | -40.23M | -17194.44% |
|---|---|---|---|
| Mar 2024 | 0 | -51.68M | |
| Oct 2025 | 0 | -68.05M | |
| Dec 2025 | 0 | -69.00M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 492511000 | 50.52M | 10.26% |
|---|---|---|---|
| Sep 2023 | 460111000 | 49.90M | 10.85% |
| Dec 2023 | 596269000 | 59.96M | 10.06% |
| Mar 2024 | 577322000 | 66.78M | 11.57% |
| Jun 2023 | -34.44M | -101.80M | 30.76M |
|---|---|---|---|
| Sep 2023 | -30.36M | 38.32M | -1.48M |
| Dec 2023 | -34.29M | -63.64M | 162.17M |
| Mar 2024 | -39.72M | -79.89M | 21.03M |
89bio alternative data
| Sep 2023 | 45 |
|---|---|
| Oct 2023 | 45 |
| Nov 2023 | 45 |
| Dec 2023 | 45 |
| Jan 2024 | 45 |
| Feb 2024 | 45 |
| Mar 2024 | 70 |
| Apr 2024 | 70 |
| May 2024 | 70 |
| Jun 2024 | 70 |
| Jul 2024 | 70 |
89bio other data
37.15%
-61.08%
of ETNB is owned by hedge funds
73
-34
12.93M
-33.48M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 4477 |
| Mar 2024 | 1350000 | 0 |
| Apr 2024 | 0 | 52718 |
| Oct 2024 | 0 | 27955 |
| Nov 2024 | 3260000 | 0 |
| Dec 2024 | 15000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | PALEKAR ROHAN director, officer.. | Common Stock | 5,000 | $7.89 | $39,450 | ||
Purchase | MCWHERTER CHARLES director | Common Stock | 10,000 | $8 | $80,000 | ||
Purchase | PALEKAR ROHAN director, officer.. | Common Stock | 10,000 | $8.35 | $83,500 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: | Pre-Funded Warrants (Right to Buy) | 3,250,000 | $0 | $3,250 | ||
Sale | LE-NGUYEN QUOC officer: See Rema.. | Common Stock | 27,955 | $8.12 | $226,995 | ||
Option | PALEKAR ROHAN director, officer.. | Common Stock | 25,000 | $1.93 | $48,250 | ||
Sale | PALEKAR ROHAN director, officer.. | Common Stock | 52,718 | $10.91 | $575,153 | ||
Option | PALEKAR ROHAN director, officer.. | Stock Option (Right to Buy) | 25,000 | $1.93 | $48,250 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director, 10 percent owner: | Common Stock | 1,350,000 | $15.35 | $20,722,500 | ||
Sale | PALEKAR ROHAN director, officer.. | Common Stock | 4,477 | $10.76 | $48,173 |
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
89bio's Pegozafermin Is Now Gaining Momentum
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement
89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy
89bio's Low Price Presents An Opportunity
Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data
89bio, Inc.: A Big Bet On NASH
89bio: Great Prospects After Excellent Phase 2 Data
-
What's the price of 89bio stock today?
One share of 89bio stock can currently be purchased for approximately $9.
-
When is 89bio's next earnings date?
Unfortunately, 89bio's (ETNB) next earnings date is currently unknown.
-
Does 89bio pay dividends?
No, 89bio does not pay dividends.
-
How much money does 89bio make?
89bio has a market capitalization of 918.31M.
-
What is 89bio's stock symbol?
89bio, Inc. is traded on the NASDAQ under the ticker symbol "ETNB".
-
What is 89bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of 89bio?
Shares of 89bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 89bio's key executives?
89bio's management team includes the following people:
- Mr. Rohan Palekar Chief Executive Officer & Director(age: 59, pay: $869,650)
- Dr. Harry Mansbach M.D. Chief Medical Officer(age: 60, pay: $650,000)
- Mr. Quoc Le-Nguyen Chief Technical Operations Officer & Head of Quality(age: 57, pay: $555,380)
-
How many employees does 89bio have?
As Jul 2024, 89bio employs 70 workers.
-
When 89bio went public?
89bio, Inc. is publicly traded company for more then 5 years since IPO on 11 Nov 2019.
-
What is 89bio's official website?
The official website for 89bio is 89bio.com.
-
Where are 89bio's headquarters?
89bio is headquartered at 142 Sansome Street, San Francisco, CA.
-
How can i contact 89bio?
89bio's mailing address is 142 Sansome Street, San Francisco, CA and company can be reached via phone at +41 54329270.
89bio company profile:
89bio, Inc.
89bio.comExchange:
NASDAQ
Full time employees:
70
Industry:
Biotechnology
Sector:
Healthcare
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
142 Sansome Street
San Francisco, CA 94104
San Francisco, CA 94104
CIK: 0001785173
ISIN: US2825591033
CUSIP: 282559103
